•  
  •  
  •  
  •  

2025-11-30 03:24:08

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura

Keywords Selected:  Tablets

Stock Report

  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • Relonchem Limited receives Marketing Authorization for its products
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • Shilpa Medicare announces the approval of Nor Ursodeoxycholic Acid Tablets 500 mg for the treatment of Non‐Alcoholic Fatty Liver Disease in India
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • Lupin launches Eslicarbazepine Acetate Tablets in the United States
  • Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE
  • Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
  • Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States
  • Eugia Pharma receives USFDA Approval for Pazopanib Tablets, 200 mg
  • Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
  • Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India
  • Alembic Pharmaceuticals announces USFDA Final Approval for Albendazole Tablets USP, 200 mg
  • Lupin Launches Mirabegron Extended-Release Tablets in the United States
  • Sun Pharma introduces a novel treatment, STARIZO in India for acute bacterial skin and skin structure infections
  • Indoco Remedies receives USFDA final ANDA approval for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation
  • Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
  • Zydus receives final approval from USFDA for Valsartan Tablets
  • Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan
  • Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
  • Zydus receives tentative approval from USFDA for Azilsartan Medoxomil Tablets, 40 mg and 80 mg
  • Alembic Pharmaceuticals announces USFDA Tentative Approval for Ivosidenib Tablets 250 mg

Latest Post

  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024